ADMA
Another day, another lawsuit notice
ADMA Biologics is back in the legal spotlight, and not in the fun, biotech-breakthrough kind of way. Levi & Korsinsky is encouraging investors who bought ADMA between August 9, 2024 and March 25, 2026 to contact the firm about a securities class action.
What’s the allegation?
The notice says the complaint centers on ADMA’s August 8, 2024 Q2 2024 report, which allegedly disclosed purchases from GenesisBPS while omitting sales to Gen. That’s lawyer-speak for: the company’s disclosures may not have told the whole story, and now someone wants to fight about it in court.
Why investors should care
This isn’t a product launch or a shiny new partnership. It’s legal baggage — the kind that can keep a stock under a microscope, add headline risk, and make every update feel a little more loaded than it should.
- More legal ads like this can keep the story alive for months
- If the underlying claims gain traction, settlement costs and distraction become part of the investment case
- Even when these notices are procedural, they can still spook retail holders who were hoping for less courtroom, more clinic
Big picture
For ADMA holders, this is another reminder that biotech investing sometimes comes with a side of legal caffeine jitters. The science may be the main act, but right now the courtroom keeps stealing the opening scene.